MET - Wiki-MPM

Novel	Interactant Symbol	Name	Associated Pathways Hide	Binding Drugs Hide	Associated Diseases Hide
Novel	DNAJA3	DnaJ heat shock protein family (Hsp40) member A3
Novel	EGFR	epidermal growth factor receptor	Signaling by ERBB2 Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants Signaling by ERBB4 SHC1 events in ERBB2 signaling SHC1 events in ERBB2 signaling PLCG1 events in ERBB2 signaling PIP3 activates AKT signaling Signaling by EGFR GRB2 events in EGFR signaling GAB1 signalosome SHC1 events in EGFR signaling EGFR downregulation GRB2 events in ERBB2 signaling PI3K events in ERBB2 signaling EGFR interacts with phospholipase C-gamma EGFR Transactivation by Gastrin Constitutive Signaling by Aberrant PI3K in Cancer Signal transduction by L1 Constitutive Signaling by EGFRvIII Inhibition of Signaling by Overexpressed EGFR RAF/MAP kinase cascade ERBB2 Regulates Cell Motility PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling ERBB2 Activates PTK6 Signaling Cargo recognition for clathrin-mediated endocytosis Clathrin-mediated endocytosis PTK6 promotes HIF1A stabilization Downregulation of ERBB2 signaling TFAP2 (AP-2) family regulates transcription of growth factors and their receptors Extra-nuclear estrogen signaling NOTCH3 Activation and Transmission of Signal to the Nucleus HCMV Early Events Estrogen-dependent nuclear events downstream of ESR-membrane signaling Signaling by ERBB2 KD Mutants Signaling by ERBB2 ECD mutants Signaling by ERBB2 TMD/JMD mutants Respiratory syncytial virus (RSV) attachment and entry Developmental Lineage of Mammary Gland Myoepithelial Cells	Cetuximab Lidocaine Gefitinib Erlotinib Lapatinib Panitumumab Alvocidib IGN311 Matuzumab Vandetanib Rindopepimut Canertinib Pelitinib Varlitinib AV-412 S-{3-[(4-ANILINOQUINAZOLIN-6-YL)AMINO]-3-OXOPROPYL}-L-CYSTEINE PD-168393 Afatinib Osimertinib Necitumumab Foreskin keratinocyte (neonatal) Depatuxizumab mafodotin Icotinib Neratinib Dacomitinib Fostamatinib Poziotinib Zalutumumab Brigatinib Olmutinib Zanubrutinib Abivertinib Mobocertinib Almonertinib Amivantamab	Laryngeal cancer Cervical cancer Oral cancer Gastric cancer Choriocarcinoma Esophageal cancer Glioma Bladder cancer
Novel	EPHA2	EPH receptor A2	EPH-Ephrin signaling EPH-Ephrin signaling EPHA-mediated growth cone collapse EPHA-mediated growth cone collapse EPH-ephrin mediated repulsion of cells EPH-ephrin mediated repulsion of cells RAC1 GTPase cycle RAC2 GTPase cycle RHOG GTPase cycle RHOU GTPase cycle RAC3 GTPase cycle RHOV GTPase cycle RND3 GTPase cycle RND2 GTPase cycle RND1 GTPase cycle	Dasatinib Phosphoaminophosphonic Acid-Adenylate Ester Regorafenib Fostamatinib
Novel	ERBB2	erb-b2 receptor tyrosine kinase 2	Signaling by ERBB2 SHC1 events in ERBB2 signaling SHC1 events in ERBB2 signaling PLCG1 events in ERBB2 signaling PIP3 activates AKT signaling GRB7 events in ERBB2 signaling Downregulation of ERBB2:ERBB3 signaling GRB2 events in ERBB2 signaling GRB2 events in ERBB2 signaling PI3K events in ERBB2 signaling Constitutive Signaling by Aberrant PI3K in Cancer Sema4D induced cell migration and growth-cone collapse RAF/MAP kinase cascade ERBB2 Regulates Cell Motility PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling ERBB2 Activates PTK6 Signaling Downregulation of ERBB2 signaling TFAP2 (AP-2) family regulates transcription of growth factors and their receptors Constitutive Signaling by Overexpressed ERBB2 Drug-mediated inhibition of ERBB2 signaling Signaling by ERBB2 KD Mutants Resistance of ERBB2 KD mutants to trastuzumab Resistance of ERBB2 KD mutants to sapitinib Resistance of ERBB2 KD mutants to tesevatinib Resistance of ERBB2 KD mutants to neratinib Resistance of ERBB2 KD mutants to osimertinib Resistance of ERBB2 KD mutants to afatinib Resistance of ERBB2 KD mutants to AEE788 Resistance of ERBB2 KD mutants to lapatinib Signaling by ERBB2 ECD mutants Signaling by ERBB2 TMD/JMD mutants Drug resistance in ERBB2 TMD/JMD mutants Developmental Lineage of Mammary Gland Luminal Epithelial Cells Developmental Lineage of Mammary Gland Myoepithelial Cells Developmental Lineage of Mammary Stem Cells	Trastuzumab Lapatinib IGN311 Trastuzumab emtansine Varlitinib AV-412 Pertuzumab Afatinib Tucatinib Tesevatinib Fostamatinib Brigatinib Margetuximab Zanubrutinib	Breast cancer Cervical cancer Cholangiocarcinoma Pancreatic cancer Gastric cancer Ovarian cancer Choriocarcinoma Endometrial Cancer Bladder cancer
Novel	FAS	Fas cell surface death receptor	Caspase activation via Death Receptors in the presence of ligand Regulation by c-FLIP RIPK1-mediated regulated necrosis CASP8 activity is inhibited TP53 Regulates Transcription of Death Receptors and Ligands Dimerization of procaspase-8 FasL/ CD95L signaling		Esophageal cancer Chronic lymphocytic leukemia (CLL) Hodgkin lymphoma Adult T-cell leukemia
Novel	FES	FES proto-oncogene, tyrosine kinase	Signaling by SCF-KIT Sema3A PAK dependent Axon repulsion SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion CRMPs in Sema3A signaling	Fostamatinib
Novel	FGFR4	fibroblast growth factor receptor 4	PI3K Cascade PIP3 activates AKT signaling betaKlotho-mediated ligand binding FGFR4 mutant receptor activation FGFR4 ligand binding and activation Constitutive Signaling by Aberrant PI3K in Cancer Phospholipase C-mediated cascade; FGFR4 FRS-mediated FGFR4 signaling SHC-mediated cascade:FGFR4 PI-3K cascade:FGFR4 Negative regulation of FGFR4 signaling Signaling by FGFR4 in disease RAF/MAP kinase cascade PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling	Heparin Ponatinib Lenvatinib Infigratinib Erdafitinib Pemigatinib Futibatinib
Novel	FGR	FGR proto-oncogene, Src family tyrosine kinase	FCGR activation Platelet sensitization by LDL Neutrophil degranulation FCGR3A-mediated IL10 synthesis FCGR3A-mediated phagocytosis	Dasatinib Fostamatinib Zanubrutinib
Novel	FOXA3	forkhead box A3	Regulation of gene expression in beta cells
Novel	FZR1	fizzy and cell division cycle 20 related 1	Autodegradation of Cdh1 by Cdh1:APC/C SCF-beta-TrCP mediated degradation of Emi1 APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1 Conversion from APC/C:Cdc20 to APC/C:Cdh1 in late anaphase Regulation of APC/C activators between G1/S and early anaphase Phosphorylation of Emi1 Senescence-Associated Secretory Phenotype (SASP) Assembly of the pre-replicative complex CDK-mediated phosphorylation and removal of Cdc6 Cyclin A/B1/B2 associated events during G2/M transition Cyclin A:Cdk2-associated events at S phase entry Transcriptional Regulation by VENTX Aberrant regulation of mitotic exit in cancer due to RB1 defects Antigen processing: Ubiquitination & Proteasome degradation
Novel	GAB1	GRB2 associated binding protein 1	PI3K Cascade Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants PIP3 activates AKT signaling GAB1 signalosome PI3K events in ERBB2 signaling Constitutive Signaling by Aberrant PI3K in Cancer Constitutive Signaling by EGFRvIII PI-3K cascade:FGFR1 PI-3K cascade:FGFR2 PI-3K cascade:FGFR3 PI-3K cascade:FGFR4 Signaling by FGFR2 in disease Signaling by FGFR4 in disease Signaling by FGFR1 in disease Signaling by FGFR3 in disease PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling MET activates PI3K/AKT signaling RET signaling MET activates PTPN11 MET activates RAP1 and RAC1 MET receptor recycling Erythropoietin activates Phosphoinositide-3-kinase (PI3K) Activated NTRK2 signals through PI3K Signaling by ERBB2 KD Mutants Signaling by ERBB2 ECD mutants
Novel	GLIS2	GLIS family zinc finger 2			Nephronophthisis-medullary cystic kidney disease, including; Nephronophthisis (NPH) ; Nephronophthisis-like nephropathy 1; Medullary cystic kidney disease 1; Medullary cystic kidney disease 2 (MSKD2)
Novel	GLMN	glomulin, FKBP associated protein	Antigen processing: Ubiquitination & Proteasome degradation		Venous malformations, including: Sporadic venous malformation; Cutaneomucosal venous malformation; Glomuvenous malformation
Novel	GRB14	growth factor receptor bound protein 14	Tie2 Signaling
Novel	GRB2	growth factor receptor bound protein 2	Interleukin-15 signaling Interleukin-15 signaling Signaling by CSF3 (G-CSF) Signaling by CSF3 (G-CSF) STAT5 activation downstream of FLT3 ITD mutants Signaling by FLT3 ITD and TKD mutants Signaling by FLT3 ITD and TKD mutants Signaling by ALK fusions and activated point mutants Signaling by LTK	Pegademase 4-[(10s,14s,18s)-18-(2-Amino-2-Oxoethyl)-14-(1-Naphthylmethyl)-8,17,20-Trioxo-7,16,19-Triazaspiro[5.14]Icos-11-En-10-Yl]Benzylphosphonic Acid
Novel	GRB7	growth factor receptor bound protein 7	GRB7 events in ERBB2 signaling Signaling by SCF-KIT Downstream signal transduction Tie2 Signaling RET signaling RND1 GTPase cycle
Novel	HCK	HCK proto-oncogene, Src family tyrosine kinase	Nef and signal transduction FCGR activation Regulation of signaling by CBL Regulation of signaling by CBL FCGR3A-mediated IL10 synthesis FCGR3A-mediated phagocytosis Signaling by CSF3 (G-CSF) Signaling by CSF3 (G-CSF) Signaling by CSF1 (M-CSF) in myeloid cells Inactivation of CSF3 (G-CSF) signaling Inactivation of CSF3 (G-CSF) signaling FLT3 signaling through SRC family kinases	1-Ter-Butyl-3-P-Tolyl-1h-Pyrazolo[3,4-D]Pyrimidin-4-Ylamine Phosphonotyrosine Quercetin Bosutinib Fostamatinib
Novel	HGF	hepatocyte growth factor	Platelet degranulation PIP3 activates AKT signaling Interleukin-7 signaling Constitutive Signaling by Aberrant PI3K in Cancer RAF/MAP kinase cascade Interleukin-4 and Interleukin-13 signaling MET Receptor Activation Negative regulation of MET activity PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling MET activates RAS signaling MET activates PI3K/AKT signaling MET activates PTPN11 MET activates PTK2 signaling MET interacts with TNS proteins MET activates RAP1 and RAC1 MET receptor recycling MET activates STAT3 Drug-mediated inhibition of MET activation	Valproic acid Heparin O2-Sulfo-Glucuronic Acid N,O6-Disulfo-Glucosamine ABT-510 Foretinib
Novel	HGS	hepatocyte growth factor-regulated tyrosine kinase substrate	EGFR downregulation Lysosome Vesicle Biogenesis Ub-specific processing proteases Negative regulation of MET activity Cargo recognition for clathrin-mediated endocytosis Clathrin-mediated endocytosis InlB-mediated entry of Listeria monocytogenes into host cell RHOU GTPase cycle Endosomal Sorting Complex Required For Transport (ESCRT) Inhibition of membrane repair Prevention of phagosomal-lysosomal fusion RHOBTB3 ATPase cycle	Citric acid
Novel	HSH2D	hematopoietic SH2 domain containing

Search Results for: MET